最近在药物开发方面取得的进展,用于使用草药和纳米技术方法治疗疟疾
Sarvesh Bhargava1, Rohitas Deshmukh1, Hitesh Kumar Dewangan2
1Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India.
Current pharmaceutical design
|September 16, 2024
概括
纳米技术为疟疾治疗提供了一个有前途的解决方案,解决了当前药物的局限性,如溶解性差和抗药性增加. 这种方法增强了药物输送,提高了安全性和疗效,从而改善了患者的治疗结果.
科学领域:
- 医学科学 医学科学 医学科学
- 纳米技术纳米技术
- 寄生虫学的寄生虫学
背景情况:
- 疟疾影响全球超过2亿人,目前的治疗方法面临药物耐药性和生物利用性差等挑战.
- 现有的抗疟疾药物,包括素组合药物,具有诸如低水溶性和诱导耐药寄生虫的潜力等局限性.
- 由于治疗失败和耐药性增加,迫切需要开发新的,有效和安全的抗疟疾疗法.
研究的目的:
- 审查目前疟疾治疗方法的局限性.
- 探索纳米技术作为一种更安全,更有效的疟疾治疗策略的潜力.
- 讨论用于改善抗疟疾药物输送的纳米材料的最新进展.
主要方法:
- 对现有的抗疟疾疗法及其缺点的文献综述.
- 分析基于纳米技术的方法来治疗疟疾.
- 检查纳米材料进步及其在药物输送系统中的应用.
主要成果:
- 纳米技术提供了显著的优势,包括高药物载荷能力,有针对性的输送,生物相容性和低毒性.
- 与传统治疗相比,基于纳米颗粒的抗疟疾药物显示出优越的治疗效益,增强的安全性和成本效益.
- 纳米技术通过更有效,更安全的疟疾干预措施提高了患者的服从性.
结论:
- 纳米技术为开发下一代抗疟疾疗法提供了可行和先进的替代方案.
- 解决目前疟疾治疗的局限性需要创新的方法,例如基于纳米技术的药物输送.
- 对纳米材料及其应用的进一步研究对未来的疟疾控制和根除工作具有重大前景.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...